WO2006031683A3 - Compositions containing uridine, and methods utilizing same - Google Patents

Compositions containing uridine, and methods utilizing same

Info

Publication number
WO2006031683A3
WO2006031683A3 PCT/US2005/032312 US2005032312W WO2006031683A3 WO 2006031683 A3 WO2006031683 A3 WO 2006031683A3 US 2005032312 W US2005032312 W US 2005032312W WO 2006031683 A3 WO2006031683 A3 WO 2006031683A3
Authority
WO
WIPO (PCT)
Prior art keywords
compositions containing
methods utilizing
utilizing same
containing uridine
uridine
Prior art date
Application number
PCT/US2005/032312
Other languages
French (fr)
Other versions
WO2006031683A2 (en
Inventor
Richard J Wurtman
Carol Watkins
Original Assignee
Massachusetts Inst Technology
Richard J Wurtman
Carol Watkins
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/941,025 external-priority patent/US20050203053A1/en
Priority claimed from US10/944,269 external-priority patent/US8143234B2/en
Priority claimed from US10/972,777 external-priority patent/US8314064B2/en
Application filed by Massachusetts Inst Technology, Richard J Wurtman, Carol Watkins filed Critical Massachusetts Inst Technology
Priority to JP2007532388A priority Critical patent/JP2008513453A/en
Priority to EP05796529A priority patent/EP1802314A4/en
Priority to CA2579851A priority patent/CA2579851C/en
Priority to AU2005285090A priority patent/AU2005285090A1/en
Publication of WO2006031683A2 publication Critical patent/WO2006031683A2/en
Publication of WO2006031683A3 publication Critical patent/WO2006031683A3/en
Priority to IL181810A priority patent/IL181810A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)

Abstract

The present invention is directed to methods of improving cognitive and neurological functions and increasing synthesis and release of neurotransmitters and membrane synthesis by neural cells and brain cells, comprising administering a composition comprising a uridine.
PCT/US2005/032312 2004-09-15 2005-09-13 Compositions containing uridine, and methods utilizing same WO2006031683A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
JP2007532388A JP2008513453A (en) 2004-09-15 2005-09-13 Compositions containing uridine and methods of use thereof
EP05796529A EP1802314A4 (en) 2004-09-15 2005-09-13 Compositions containing uridine, and methods utilizing same
CA2579851A CA2579851C (en) 2004-09-15 2005-09-13 Use of uridine for improving cognitive and neurological functions
AU2005285090A AU2005285090A1 (en) 2004-09-15 2005-09-13 Compositions containing uridine, and methods utilizing same
IL181810A IL181810A0 (en) 2004-09-15 2007-03-08 Compositions containing uridine, and methods utilizing same

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US10/941,025 2004-09-15
US10/941,025 US20050203053A1 (en) 1999-07-30 2004-09-15 Uridine administration improves phosphatide synthesis, synaptic transmission and cogntive function
US10/944,269 2004-09-20
US10/944,269 US8143234B2 (en) 1998-07-31 2004-09-20 Uridine administration improves phosphatide synthesis, synaptic transmission and cognitive function
US10/972,777 2004-10-26
US10/972,777 US8314064B2 (en) 1998-07-31 2004-10-26 Uridine administration stimulates membrane production

Publications (2)

Publication Number Publication Date
WO2006031683A2 WO2006031683A2 (en) 2006-03-23
WO2006031683A3 true WO2006031683A3 (en) 2006-12-21

Family

ID=36060581

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/032312 WO2006031683A2 (en) 2004-09-15 2005-09-13 Compositions containing uridine, and methods utilizing same

Country Status (6)

Country Link
EP (1) EP1802314A4 (en)
JP (2) JP2008513453A (en)
CN (1) CN102600199A (en)
AU (1) AU2005285090A1 (en)
CA (1) CA2579851C (en)
WO (1) WO2006031683A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101415328B (en) * 2006-01-30 2014-03-05 麻省理工学院 Methods and compositions for ameliorating or inhibiting decline in memory or intelligence or improving same

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8143234B2 (en) 1998-07-31 2012-03-27 Massachusetts Institute Of Technology Uridine administration improves phosphatide synthesis, synaptic transmission and cognitive function
US8314064B2 (en) 1998-07-31 2012-11-20 Massachusetts Institute Of Technology Uridine administration stimulates membrane production
CN102600199A (en) * 2004-09-15 2012-07-25 麻省理工学院 Methods for increasing cytidine levels in vivo and treating cytidine-dependent human diseases
WO2009002148A1 (en) * 2007-06-27 2008-12-31 N.V. Nutricia Food composition for prodromal dementia patients
WO2009002145A1 (en) 2007-06-26 2008-12-31 N.V. Nutricia Lipid composition for improving function of brain functioning
WO2009002146A1 (en) 2007-06-26 2008-12-31 N.V. Nutricia Supporting activities of daily living
WO2009082203A1 (en) 2007-12-20 2009-07-02 N.V. Nutricia Liquid nucleotides/nucleosides-containing product
US20100331258A1 (en) * 2007-06-26 2010-12-30 N.V. Nutricia memory in subjects with mini-mental state examination of 24-26
WO2009057994A1 (en) 2007-11-02 2009-05-07 N.V. Nutricia Unit dosage for brain health
WO2012125020A1 (en) 2011-03-14 2012-09-20 N.V. Nutricia Method for treating neurotrauma
HUE039871T2 (en) * 2013-03-13 2019-02-28 Univ Tufts Uridine nucleoside derivatives, compositions and methods of use
CN106822393A (en) * 2017-02-17 2017-06-13 福建康是美生物科技有限公司 A kind of health-caring capsule for strengthening memory
MX2020007866A (en) * 2018-02-01 2020-12-03 Wellstat Therapeutics Corp Compositions and devices for systemic delivery of uridine.
CN115120607A (en) * 2022-06-07 2022-09-30 珍奥集团股份有限公司 Application of nucleotide mixture in preparation for preventing and treating Alzheimer's disease
WO2024058276A1 (en) * 2022-09-16 2024-03-21 ヤマサ醤油株式会社 Agent and method for improving composite memory of normal person
CN115737666B (en) * 2022-11-24 2024-03-26 暨南大学 Application of uridine diphosphate glucose in preparation of anti-aging products

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010005719A1 (en) * 1998-08-31 2001-06-28 Von Borstel Reid W. Compositions and methods for treatment of mitochondrial diseases

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3011A (en) * 1843-03-21 Improvement in water-wheels
IT1290781B1 (en) * 1996-05-28 1998-12-10 Polifarma Spa ACTIVE THERAPEUTIC AGENT FOR THE TREATMENT OF NEURONAL DEGENERATIVE DISEASES.
HUP0000124A3 (en) * 1996-05-28 2000-06-28 Polifarma Spa Uridine-comprising therapeutic active agent for treatment of neurodegenerative disorders
ATE374029T1 (en) * 1998-07-31 2007-10-15 Massachusetts Inst Technology TREATING ALZHEIMER'S DISEASE BY INCREASE CYTIDINE LEVELS IN VIVO
JP2001233776A (en) * 2000-02-25 2001-08-28 Yamasa Shoyu Co Ltd Agent for improving lowering of learning and memorizing ability and its use
US20030114415A1 (en) * 2001-12-14 2003-06-19 Wurtman Richard J. Compositions and methods for treating and preventing memory impairment using citicoline
WO2005079250A2 (en) * 2004-02-13 2005-09-01 Cornell Research Foundation, Inc. Purines are self-renewal signals for neural stem cells, and purine receptor antagonists promote neuronal and glial differentiation therefrom
BRPI0510857A (en) * 2004-05-13 2007-12-26 Massachusetts Inst Technology effects of uridine on dopamine release
CN102600199A (en) * 2004-09-15 2012-07-25 麻省理工学院 Methods for increasing cytidine levels in vivo and treating cytidine-dependent human diseases

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010005719A1 (en) * 1998-08-31 2001-06-28 Von Borstel Reid W. Compositions and methods for treatment of mitochondrial diseases

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
"Chapter 63 Goodman & gilmans's The Pharmacological Basis of Therapeutics", vol. 8TH ED., 1990, PERGAMON PRESS, ELMSFORD, NY, article MARCUS ET AL.: "Water Soluble Vitamins", pages: 1530, XP008074108 *
See also references of EP1802314A4 *
SITARAM ET AL.: "Human Serial Learning: Enhancement with Arecholine and Choline and Impairment with Scopolamine", SCIENCE, vol. 201, 21 July 1978 (1978-07-21), pages 274 - 276, XP003004900 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101415328B (en) * 2006-01-30 2014-03-05 麻省理工学院 Methods and compositions for ameliorating or inhibiting decline in memory or intelligence or improving same

Also Published As

Publication number Publication date
AU2005285090A1 (en) 2006-03-23
JP2008513453A (en) 2008-05-01
CN102600199A (en) 2012-07-25
JP2013064026A (en) 2013-04-11
CA2579851C (en) 2018-09-04
CA2579851A1 (en) 2006-03-23
EP1802314A2 (en) 2007-07-04
JP6141643B2 (en) 2017-06-07
EP1802314A4 (en) 2011-02-23
WO2006031683A2 (en) 2006-03-23

Similar Documents

Publication Publication Date Title
WO2006031683A3 (en) Compositions containing uridine, and methods utilizing same
TW200621716A (en) Novel compounds
WO2008070462A3 (en) N-oxides of 4,5-epoxy-morphinanium analogs
WO2006004684A8 (en) 3-aminocyclopentanecarboxamides as modulators of chemokine receptors
TW200800968A (en) Sulfoximine-substituted pyrimidines, processes for production thereof and use thereof as drugs
WO2006081583A3 (en) Methods and compositions for improving fidelity in a nucleic acid synthesis reaction
TW200611701A (en) Novel compounds
WO2006018184A3 (en) Spirocyclic cyclohexane derivatives
WO2008064353A3 (en) 7,8-saturated-4,5-epoxy-morphinanium analogs
WO2007078523A3 (en) 5-phenyl-3-benzyl-0xaz0lidin-2-0ne derivatives and related compounds as metabotropic glutamate receptor potentiators for the treatment of neurological and psychiatric disorders
WO2007027238A3 (en) Jak kinase inhibitors and their uses
PL1891004T3 (en) Pentafluorosulphanyl-substituted compound and its use for producing medicaments
WO2007000325A3 (en) Substituted 1-oxa-3,8-diazaspiro[4.5]-decan-2-on- compounds and the use thereof for producing drugs
WO2006094292A3 (en) Thienopyridine compounds, and methods of use thereof
WO2005115392A3 (en) 3-(4-heteroarylcyclohexylamino) cyclopentanecarboxamides as modulators of chemokine receptors
GB0510143D0 (en) Novel compounds A1
WO2007006870A3 (en) Novel carbohydrate profile compositions from human cells and methods for analysis and modification thereof
WO2008083950A8 (en) Spirocyclic tetronic acid derivatives
WO2006078886A3 (en) Compounds and compositions as wnt signaling pathway modulators
WO2008098180A3 (en) Complementary personal lubrificant compositions and delivery system
HK1092134A1 (en) Preparation of 4,5-dialkyl-3-acyl-pyrrole-2-carboxylic acid derivatives by fischer-fink type synthesis and subsequent acylation
ZA201003221B (en) Tea composition and process for the manufacture thereof
WO2006122769A3 (en) Substituted spiro compounds and their use for producing pain-relief drugs
WO2007104485A3 (en) Substituted imidazo[2,1-b]thiazole compounds and their use for producing drugs
WO2007002722A3 (en) Synthesis of anastrozole and purification of one of its intermediate

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 181810

Country of ref document: IL

Ref document number: 2579851

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2007532388

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2005285090

Country of ref document: AU

Ref document number: 1009/KOLNP/2007

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2005796529

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2005285090

Country of ref document: AU

Date of ref document: 20050913

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2005285090

Country of ref document: AU

DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
WWE Wipo information: entry into national phase

Ref document number: 200580039021.3

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 2005796529

Country of ref document: EP

DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)